BNC375 Alzheimer's Disease Drug Candidate Presented at Neuroscience Conference

BNC375 Alzheimer's Disease Drug Candidate Presented at Neuroscience Conference

  *BNC375 enhances episodic and working memory
  *Performance matches Donepezil (US$2.5 billion sales in 2011) in animal
    tests

ADELAIDE, South Australia, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Bionomics Limited
(ASX:BNO) today announced that new data on BNC375, its drug candidate with
potential for the treatment of memory loss in Alzheimers Disease, will be
presented at the 33rd Annual Meeting of the Australian Neuroscience Society
taking place in Melbourne from 3 – 6 February 2013 at the Melbourne Convention
Centre.

BNC375, which is a positive allosteric modulator of the α7 nicotinic
acetylcholine receptor (α7 nAChR), will be the focus of Poster #143 which will
be exhibited today Monday, 4 February 2013 from 12.30pm -2.30pm.

The poster highlights data demonstrating the in vivo memory enhancing
properties of this drug candidate in two animal models of cognitive impairment
as well as data on the action of BNC375 on the receptor. The animal model data
indicates that BNC375 enhances both episodic memory and working memory and
that it has equivalent performance compared to Donepezil, a Pfizer product
marketed as Aricept with reported US$2.5 billion sales in 2011. BNC375 has a
100-fold therapeutic dose range, from 0.1 to 10 mg/kg and has demonstrated a
wide therapeutic window in the preclinical studies conducted to date.

"BNC375 targets Alzheimer's disease and other conditions which are associated
with significant memory loss," said Dr Deborah Rathjen, Bionomics' CEO and
Managing Director.

"This latest drug candidate to come from our technology platform conforms to
Bionomics' focus on developing well differentiated drug candidates to treat
serious conditions such as Alzheimer's disease, Schizophrenia and Parkinson's
disease amongst others," she added.

There is a large body of evidence implicating the α7 nAChR in the
pathophysiology of several neurodegenerative and neuropsychiatric diseases.
Modulation of this receptor enhances cognitive processes, for example working
memory and attention, which are compromised in these disorders.

In 2010 the estimated worldwide costs of dementia, including direct and
indirect costs of care, was $604 billion with an estimated 35.6 million people
worldwide affected by dementia. This is expected to double every 20 years
reaching 65.7 million in 2030 and 115.4 million in 2050. In the US alone an
estimated 5.3 million people have Alzheimer's disease including 14% of people
over 71 years of age (Source: Business Insights, May 2011, Advances in
Alzheimer's Disease Drug Discovery: Innovations, challenges, and future
directions).

You can view a copy of the poster on the Bionomics website.
www.bionomics.com.au

About Bionomics Limited

Bionomics (ASX:BNO) is an Australian based international biotechnology company
which discovers and develops innovative therapeutics for cancer and diseases
of the central nervous system. Bionomics has small molecule product
development programs in the areas of cancer, anxiety, memory loss and
autoimmune disorders, several of which are in or approaching clinical
development stage. Its oncology approach includes cancer stem cell
therapeutics as well as vascular disruption in solid tumours.

BNC105, which is undergoing Phase II clinical development for the treatment in
a range of solid tumour types, is based upon the identification of a novel
compound that potently and selectively restricts blood flow within tumours.
BNC105 offers blockbuster potential if successfully developed. A clinical
program is also underway for the treatment of anxiety disorders and depression
based on IW-2143(BNC210), a novel compound which stimulates neurite outgrowth.
IW-2143 is partnered with Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four
proprietary technology platforms: Angene®, a drug discovery platform which
incorporates a variety of genomics tools to identify and validate novel
angiogenesis targets (involved in the formation of new blood vessels);
MultiCore®, a diversity orientated chemistry platform for the discovery of
small molecule drugs; ionX® , a set of novel technologies for the
identification of drugs targeting ion channels for diseases of the central
nervous system; and CSC Rx Discovery™, which identifies antibody and small
molecule therapeutics that inhibit the growth of cancer stem cells. These
platforms drive Bionomics' pipeline and underpin its established business
strategy of securing partners for its key compounds.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of
the United States' Private Securities Litigation Reform Act of 1995. Any
statements contained in this presentation that relate to prospective events or
developments, including, without limitation, statements made regarding
Bionomics' development candidates BNC105, IW-2143(BNC210), our acquisition of
Eclipse Therapeutics and ability to develop products from their platform, its
licensing deal with Ironwood Pharmaceuticals, drug discovery programs and
pending patent applications are deemed to be forward-looking statements. Words
such as "believes," "anticipates," "plans," "expects," "projects,"
"forecasts," "will" and similar expressions are intended to identify
forward-looking statements.

There are a number of important factors that could cause actual results or
events to differ materially from those indicated by these forward-looking
statements, including risks related to our available funds or existing funding
arrangements, a downturn in our customers' markets, our failure to introduce
new products or technologies in a timely manner, Ironwood's decisions to
continue or not continue development of IW-2143, regulatory changes, risks
related to our international operations, our inability to integrate acquired
businesses and technologies into our existing business and to our competitive
advantages, as well as other factors. Results of studies performed on
competitors products may vary from those reported when tested in different
settings.

Subject to the requirements of any applicable legislation or the listing rules
of any stock exchange on which our securities are quoted, we disclaim any
intention or obligation to update any forward-looking statements as a result
of developments occurring after the date of this presentation.

CONTACT: Dr Deborah Rathjen
         CEO & Managing Director
         Bionomics Limited
         +618 8354 6101 /
         0418 160 425
         drathjen@bionomics.com.au
        
         Ms Melanie Young
         CFO & Company Secretary
         Bionomics Limited
         +61 8 8354 6100